Giorgia N. Saporiti

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy.

Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy.

Journal: American journal of hematology

Published: May 27, 2026

Real-world approaches to preventing acute myeloid leukemia relapse after allogeneic transplantation: a national survey by GITMO (Gruppo Italiano Trapianto Midollo Osseo).

Real-world approaches to preventing acute myeloid leukemia relapse after allogeneic transplantation: a national survey by GITMO (Gruppo Italiano Trapianto Midollo Osseo).

Journal: Bone marrow transplantation

Published: April 01, 2026

A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission.

A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission.

Journal: Bone marrow transplantation

Published: January 21, 2026

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.

Journal: American journal of hematology

Published: August 22, 2025

Treosulfan-based double-alkylator conditioning in myelofibrosis: An Italian retrospective multicenter analysis.

Treosulfan-based double-alkylator conditioning in myelofibrosis: An Italian retrospective multicenter analysis.

Journal: Bone marrow transplantation

Published: August 04, 2025

Danazol treatment for poor graft function after hematopoietic stem cell transplantation: a single centre experience.

Danazol treatment for poor graft function after hematopoietic stem cell transplantation: a single centre experience.

Journal: Bone marrow transplantation

Published: August 02, 2025

Unrelated donor transplantation for relapsed refractory aplastic anemia, with quadruple GvHD prophylaxis.

Unrelated donor transplantation for relapsed refractory aplastic anemia, with quadruple GvHD prophylaxis.

Journal: Bone marrow transplantation

Published: April 13, 2025

GVHD in the era of checkpoint inhibition in Hodgkin lymphoma.

GVHD in the era of checkpoint inhibition in Hodgkin lymphoma.

Journal: Blood advances

Published: January 14, 2025

Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial.

Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial.

Journal: Blood advances

Published: October 24, 2024

Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial.

Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial.

Journal: Blood cancer journal

Published: June 17, 2024

Off-the-Shelf Cord-Blood Mesenchymal Stromal Cells: Production, Quality Control, and Clinical Use.

Off-the-Shelf Cord-Blood Mesenchymal Stromal Cells: Production, Quality Control, and Clinical Use.

Journal: Cells

Published: May 15, 2024

Long-term outcome of autologous haematopoietic stem cell transplantation in patients with systemic sclerosis: a comparison with patients treated with rituximab and with traditional immunosuppressive agents.

Long-term outcome of autologous haematopoietic stem cell transplantation in patients with systemic sclerosis: a comparison with patients treated with rituximab and with traditional immunosuppressive agents.

Journal: Arthritis research & therapy

Published: April 29, 2024

Showing 1-12 of 26

Last Updated: 09/26/2026